title: Does the kidney injury molecule-1 predict cisplatin-induced kidney injury in early stage?
abstract: BACKGROUND
  It is not possible to diagnose acute kidney injury (AKI) in early stages with traditional biomarkers. Kidney injury molecule-1 (KIM-1) is a novel biomarker promising the diagnosis of AKI in early stages. We studied whether urinary and serum KIM-1 (KIM-1 U and KIM-1 S ) concentrations were useful in predicting cisplatin-induced AKI in early stages.
  
  
  METHODS
  We prospectively analysed 22 patients on cisplatin treatment. KIM-1 S and KIM-1 U concentrations were assessed in the samples of the patients on four different time periods (before treatment [BT], first [AT1], third [AT3] and fifth [AT5] day after treatment).
  
  
  RESULTS
  KIM-1 U concentrations on the first day after cisplatin treatment in patients with AKI were significantly increased compared to both KIM-1 U concentrations of the same patients BT (P=0.009) and to AT1-KIM-1 U concentrations of the patients without AKI (P=0.008). A receiver operating characteristic analysis revealed that AT1-KIM-1 U concentrations may predict AKI with an 87.5% sensitivity and 93.3% specificity (area under the curve=0.94). KIM-1 S concentrations were not significantly changed between BT and AT periods.
  
  
  CONCLUSIONS
  KIM-1 U concentrations may predict cisplatin-induced AKI in early stages with high sensitivity and specificity.
authors.affiliation: Department of Medical Biochemistry, Faculty of Medicine, Abant Izzet Baysal University, Bolu, Turkey btekce@yahoo.com.
authors.forename: Buket Kin
authors.initials: BK
authors.lastname: Tekce
authors.affiliation: Department of Medical Oncology, Faculty of Medicine, Abant Izzet Baysal University, Bolu, Turkey.
authors.forename: Ummugul
authors.initials: U
authors.lastname: Uyeturk
authors.affiliation: Department of Nephrology, Faculty of Medicine, Abant Izzet Baysal University, Bolu, Turkey.
authors.forename: Hikmet
authors.initials: H
authors.lastname: Tekce
authors.affiliation: Department of Urology, Faculty of Medicine, Abant Izzet Baysal University, Bolu, Turkey.
authors.forename: Ugur
authors.initials: U
authors.lastname: Uyeturk
authors.affiliation: Department of Internal Medicine, Faculty of Medicine, Abant Izzet Baysal University, Bolu, Turkey.
authors.forename: Gulali
authors.initials: G
authors.lastname: Aktas
authors.affiliation: Department of Anaesthesiology and Reanimation, Faculty of Medicine, Abant Izzet Baysal University, Bolu, Turkey.
authors.forename: Akcan
authors.initials: A
authors.lastname: Akkaya
mesh_terms: D058186:Acute Kidney Injury / Q000097:blood / Q000139:chemically induced / Q000175:diagnosis* / Q000652:urine*; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D015415:Biomarkers / Q000097:blood / Q000652:urine; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects*; D042241:Early Diagnosis; D005260:Female; D000072596:Hepatitis A Virus Cellular Receptor 1; D006801:Humans; D007668:Kidney / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008175:Lung Neoplasms / Q000188:drug therapy / Q000473:pathology; D008297:Male; D008562:Membrane Glycoproteins / Q000097:blood / Q000652:urine*; D008875:Middle Aged; D011379:Prognosis; D011446:Prospective Studies; D012372:ROC Curve; D011991:Receptors, Virus / Q000097:blood; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; D015415:Biomarkers; C491143:HAVCR1 protein, human; D000072596:Hepatitis A Virus Cellular Receptor 1; D008562:Membrane Glycoproteins; D011991:Receptors, Virus; D002945:Cisplatin
keywords: Kidney injury molecule-1; acute kidney injury; biomarker; cisplatin